Tirzepatide
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Tirzepatide is listed as metabolic / gip+glp-1 agonist.
- •Type 2 Diabetes
- •Obesity
Regulatory status: FDA-Approved Rx.
Structure & Properties
Compound: Tirzepatide; also known as Mounjaro, Zepbound.
Pharmacologic class: Metabolic / GIP+GLP-1 Agonist.
Known delivery routes: Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Dual GIP + GLP-1 receptor agonist — synergistic effect on insulin secretion, appetite suppression, and adiposity reduction.
- •Superior weight loss vs GLP-1 alone (up to ~22%)
- •HbA1c reduction ~2.0–2.5%
- •Improved lipids and BP
Human Research
Evidence grade: Clinical RCT (Phase III)
Clinical RCT (Phase III). Phase III SURPASS/SURMOUNT programs.
Laboratory Research
Phase III SURPASS/SURMOUNT programs
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Once weekly, same day each week, any time, with or without food. Rotate injection sites (abdomen/thigh/upper arm).
Potential interactions and combinations to avoid
- •Other GLP-1s (Semaglutide, Liraglutide, Exenatide) or dual/triple agonists (Retatrutide, Survodutide)
- •Sulfonylureas / insulin without dose reduction
- •MTC / MEN2 history — contraindicated
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •GI side effects (nausea, vomiting, constipation)
- •Gallbladder disease
- •Hypoglycemia with sulfonylureas/insulin
- •Thyroid C-cell tumor warning
Contraindications
- •MTC / MEN-2
- •Pregnancy
- •Severe gastroparesis
- •Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
- •History of pancreatitis or unexplained elevated lipase/amylase
- •Gastroparesis, severe GERD, or chronic gastrointestinal motility disorder
- •History of symptomatic gallstones or biliary disease
- •Active eating disorder, malnutrition, or BMI already in the underweight range
- •Type 1 diabetes as monotherapy for glycemic control
- •Planned surgery/anesthesia without pre-procedure fasting adjustment (aspiration risk)
- •Proliferative diabetic retinopathy with rapid glycemic lowering
- •Severe renal impairment with ongoing dehydration or vomiting
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 2.5–15 mg/week
Frequency: Weekly
Cycling: Continuous; 4-week titration steps from 2.5 → 15 mg.
Subcutaneous (Mounjaro / Zepbound)
Once weekly.
Auto-injector pen or U-100 insulin syringe for compounded vials. Abdomen, thigh, or upper arm. Rotate sites weekly. Refrigerate; unused pen ≤ 21 days at room temp.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Cagrilintide (research combos) for satiety
- •Protein-forward diet + resistance training
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Tirzepatide?
In plain words
Tirzepatide, also called Mounjaro or Zepbound, is a prescription medicine for type 2 diabetes and obesity. It activates two hormone signals that help the body release insulin, reduce appetite, and lower body fat. Researchers study its effects on blood sugar and weight, and large clinical trials support its approved uses. Risks include nausea, vomiting, constipation, gallbladder disease, and low blood sugar when combined with insulin or certain diabetes pills called sulfonylureas; it also carries a warning about tumors in specific thyroid cells.
Technical definition
Tirzepatide (Mounjaro, Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Activation of these receptors has synergistic effects on insulin secretion, appetite suppression, and reduction of adiposity. It is an FDA-approved prescription medication for type 2 diabetes and obesity, supported by Phase III randomized controlled trials.
Function
Dosing
Recommended Time of Day
Same day each week, any time of day — with or without food.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
- Upper arm / deltoid — Back of the upper arm for SubQ; 2 in below the shoulder bone for IM.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous; 4-week titration steps from 2.5 → 15 mg.
Timing & Interactions
- ·Other GLP-1s (Semaglutide, Liraglutide, Exenatide) or dual/triple agonists (Retatrutide, Survodutide)
- ·Sulfonylureas / insulin without dose reduction
- ·MTC / MEN2 history — contraindicated
- ·Cagrilintide (research combos) for satiety
- ·Protein-forward diet + resistance training
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Tirzepatide and sync them to Vial Lab.
Benefits
- ·Superior weight loss vs GLP-1 alone (up to ~22%)
- ·HbA1c reduction ~2.0–2.5%
- ·Improved lipids and BP
Risks
- ·GI side effects (nausea, vomiting, constipation)
- ·Gallbladder disease
- ·Hypoglycemia with sulfonylureas/insulin
- ·Thyroid C-cell tumor warning
Contraindications
- ·MTC / MEN-2
- ·Pregnancy
- ·Severe gastroparesis
- ·Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
- ·History of pancreatitis or unexplained elevated lipase/amylase
- ·Gastroparesis, severe GERD, or chronic gastrointestinal motility disorder
- ·History of symptomatic gallstones or biliary disease
- ·Active eating disorder, malnutrition, or BMI already in the underweight range
- ·Type 1 diabetes as monotherapy for glycemic control
- ·Planned surgery/anesthesia without pre-procedure fasting adjustment (aspiration risk)
- ·Proliferative diabetic retinopathy with rapid glycemic lowering
- ·Severe renal impairment with ongoing dehydration or vomiting
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx
Veterinary Use (Pets)
No established veterinary protocol for Tirzepatide. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.
- 1.Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503.Read published work Link not opening? Search Google Scholar
- 2.Jastreboff AM et al. Tirzepatide for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205.Read published work Link not opening? Search Google Scholar